USCIS Drops Skin Test for TB Blood Test on I-693

Immigration medical exams have moved away from one of their longest-standing diagnostic tools. Panel physicians and civil surgeons no longer use the tuberculin skin test to screen permanent-residence applicants for tuberculosis; as of October 1, 2024, an interferon-gamma release assay, or IGRA, blood test is required instead.

The switch addresses a known limitation of the older skin test: it can produce false positives in people who received the BCG vaccine, which is common outside the United States and given to many applicants as children. IGRA tests, such as the QuantiFERON-TB Gold Plus assay, are not affected by prior BCG vaccination, generally require only a single clinic visit rather than a return visit to read results, and offer a broader assessment of immune response by testing for both CD4 and CD8 T-cell reactions.

Diagnostic requirements for other conditions have also been standardized around more sensitive testing. Gonorrhea screening now relies on Nucleic Acid Amplification Testing, which detects the bacteria’s genetic material and is markedly more sensitive than older culture-based methods; gram stains are not accepted for immigration screening purposes. NAAT can be run on a urine sample or a self-collected swab, and current guidance calls for using the least invasive option available. For hepatitis B, a positive surface antibody titer of 10 mIU/mL or greater is accepted as proof of immunity in place of vaccination records, with the vaccine series required only if that titer comes back negative.

Vaccine handling inside civil surgeon clinics is under similar scrutiny. Most vaccines must be stored between 2°C and 8°C, but some — including certain MMR and varicella-containing vaccines — require frozen storage between roughly -50°C and -15°C. Public health guidance calls for digital, continuous temperature monitoring with alarms and calibration traceable to National Institute of Standards and Technology standards; consumer-grade or food-service thermometers are not considered adequate. Combination dormitory-style refrigerator-freezer units are specifically flagged as unsuitable because of uneven freezing. Vaccine Vial Monitors, which change color if a vaccine has been exposed to excess heat, offer clinics an additional, low-tech check on a dose’s usability.

Further out, researchers are working on vaccines that would loosen the cold-chain requirements that make this equipment necessary in the first place. A polio vaccine designed to remain stable at room temperature for weeks, without refrigeration, has been developed and tested in animal models, and microarray patch formulations of measles and rubella vaccines are being explored for their ability to withstand storage at higher temperatures for months at a time. Neither is part of routine I-693 screening yet, but both point toward simpler logistics for clinics if they reach clinical use.

The QuantiFERON-TB Gold Plus assay adds CD8 T-cell stimulating antigens to the CD4 antigens used in earlier tests, giving a broader picture of immune response to tuberculosis.

For applicants, the practical implication is straightforward: expect a blood draw rather than a skin test for TB screening, and expect civil surgeons to rely on urine or swab-based testing rather than older culture methods for other required screenings.